As we move deeper into the era of precision medicine, our researchers are constantly evolving our drug development process to facilitate the next generation of therapies.
Clinical trial design is just one of those areas.
Clinical trials play an essential role in drug development, but in their traditional form require large numbers of participants and extensive time, only to sometimes deliver “one-drug-fits-most” treatment options.
The push towards precision medicine has necessitated a revolution in clinical trial design. A revolution that many, including our scientists within AstraZeneca, believe could hold the key to improved efficiencies and greater probabilities of success for delivering the future of precision therapies.
Understanding Conventional Multi-Drug Studies
The conventional multi-drug study approach was introduced during the mid-1940’s. Within its design, two or more treatments are compared in a pre-defined population, for a set period or until a certain number of patient outcomes have been observed.
Once completed, the results from each intervention group are reviewed and performance relative to predefined endpoints is assessed for statistical significance. Any trends observed within the tertiary endpoints or additional signals identified in the findings are then slated for additional study.
The challenge with the conventional study approach, is that it does not allow researchers to adapt to the results they are seeing throughout a study. As a result, trials that take years to run, with participation from thousands of patients, can return inconclusive results because teams were not able to adapt to observed trends as they were occurring. These delays can necessitate additional studies leading to greater demands on patients and resources.
Platform Trials and the Promise of Responsive Adaptation
Platform trials may offer a solution.
These innovative trials are designed with an open master protocol, which allows for multiple treatments to enter or exit the trial over the course of the study, providing researchers the ability to adapt to observed results throughout a study.
This flexibility allows teams to drop treatments for futility, declare one or more treatments superior, or even add new treatments to be tested during a trial, allowing clinicians to better meet the unique needs of patient populations within a study.
As a result, platform trials offer the promise of more efficient trials, capable of finding the same beneficial treatments in less time, with lower numbers of patient participants.
Moving forward, AstraZeneca is continuing to expand our use of platform and other innovative trial designs – all intended to improve our ability to turn science into medicines.